CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 81 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $7,959,000 | -78.2% | 564,102 | -75.8% | 0.11% | -83.4% |
| Q3 2020 | $36,491,000 | -10.6% | 2,328,698 | 0.0% | 0.67% | -16.1% |
| Q2 2020 | $40,799,000 | +41.5% | 2,328,698 | +18.7% | 0.80% | -12.7% |
| Q1 2020 | $28,830,000 | -38.7% | 1,961,209 | +4.6% | 0.91% | -36.2% |
| Q4 2019 | $47,049,000 | +66.8% | 1,875,209 | 0.0% | 1.43% | -15.1% |
| Q3 2019 | $28,203,000 | -39.8% | 1,875,209 | 0.0% | 1.68% | -33.3% |
| Q2 2019 | $46,880,000 | +9.8% | 1,875,209 | 0.0% | 2.52% | +36.8% |
| Q1 2019 | $42,680,000 | -24.1% | 1,875,209 | 0.0% | 1.84% | -43.8% |
| Q4 2018 | $56,238,000 | +15.4% | 1,875,209 | +10.2% | 3.27% | +25.6% |
| Q3 2018 | $48,734,000 | – | 1,701,017 | – | 2.60% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |